Rodrik-Outmezguine V - Search Results

1

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. Schwartz S, et al. Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24. Cancer Cell. 2015. PMID: 25544636 Free PMC article.

2

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N. Rodrik-Outmezguine VS, et al. Cancer Discov. 2011 Aug;1(3):248-59. doi: 10.1158/2159-8290.CD-11-0085. Epub 2011 Jun 17. Cancer Discov. 2011. PMID: 22140653 Free PMC article.

3

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. Chandarlapaty S, et al. Cancer Cell. 2011 Jan 18;19(1):58-71. doi: 10.1016/j.ccr.2010.10.031. Epub 2011 Jan 6. Cancer Cell. 2011. PMID: 21215704 Free PMC article.

4

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N. Will M, et al. Cancer Discov. 2014 Mar;4(3):334-47. doi: 10.1158/2159-8290.CD-13-0611. Epub 2014 Jan 16. Cancer Discov. 2014. PMID: 24436048 Free PMC article.

5

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Rodrik-Outmezguine VS, et al. Nature. 2016 Jun 9;534(7606):272-6. doi: 10.1038/nature17963. Epub 2016 May 18. Nature. 2016. PMID: 27279227 Free PMC article.

6

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J. Elkabets M, et al. Sci Transl Med. 2013 Jul 31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747. Sci Transl Med. 2013. PMID: 23903756 Free PMC article.

7

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Yao Z, et al. Among authors: rodrik outmezguine vs. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2. Nature. 2017. PMID: 28783719 Free PMC article.

8

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA. Yellen P, et al. Cell Cycle. 2011 Nov 15;10(22):3948-56. doi: 10.4161/cc.10.22.18124. Epub 2011 Nov 15. Cell Cycle. 2011. PMID: 22071574 Free PMC article.

9

Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.

Golfmann K, Meder L, Koker M, Volz C, Borchmann S, Tharun L, Dietlein F, Malchers F, Florin A, Büttner R, Rosen N, Rodrik-Outmezguine V, Hallek M, Ullrich RT. Golfmann K, et al. Among authors: rodrik outmezguine v. Oncogene. 2018 Oct;37(42):5682-5693. doi: 10.1038/s41388-018-0380-3. Epub 2018 Jul 3. Oncogene. 2018. PMID: 29970903

10

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M. Rothé F, et al. Among authors: rodrik outmezguine v. Clin Cancer Res. 2019 Jun 15;25(12):3581-3588. doi: 10.1158/1078-0432.CCR-18-2521. Epub 2019 Mar 12. Clin Cancer Res. 2019. PMID: 30862692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page